What inpatient orders should be placed for a patient with alcohol use disorder, including vitamin supplementation, withdrawal management (CIWA‑Ar protocol), laboratory monitoring, and treatment of hepatic complications?

Inpatient Orders for Alcohol Users

All hospitalized patients with alcohol use disorder require thiamine 100-300 mg/day (given BEFORE any glucose-containing IV fluids), benzodiazepines for withdrawal management using a symptom-triggered CIWA-Ar protocol, electrolyte monitoring (especially magnesium), and psychiatric consultation for long-term abstinence planning. 1, 2

Essential Admission Orders

Vitamin Supplementation

• Thiamine 100-300 mg/day for 4-12 weeks minimum (prevention of Wernicke encephalopathy) 1
• Critical timing: Administer thiamine BEFORE any IV glucose-containing fluids, as glucose can precipitate acute thiamine deficiency 1
• For established Wernicke encephalopathy: increase to 100-500 mg/day for 12-24 weeks 1
• Additional vitamins and general nutritional support 1

Laboratory Monitoring

Order the following on admission and monitor serially:

• Electrolytes (83% guideline concordance) - particularly magnesium, which requires aggressive repletion 1, 3
• Hepatic function panel (75% guideline concordance) 3
• Complete blood count (assess for macrocytosis) 4
• Substance use screening (83% guideline concordance) 3
• Infection screening (only 33% guideline concordance, but critical given comorbidities) 3
• Renal function, coagulation studies if liver disease present 1

Withdrawal Management Protocol

CIWA-Ar Protocol Implementation:

The CIWA-Ar is useful for monitoring severity and guiding treatment, though it should NOT be used for diagnosis of AWS (can be falsely elevated in sepsis, hepatic encephalopathy, anxiety disorders) 1. The 2018 EASL guidelines recommend symptom-triggered regimens over fixed-dose schedules to prevent drug accumulation 2.

Benzodiazepine Selection (Critical Decision Point):

• For patients WITHOUT liver failure: Long-acting benzodiazepines (chlordiazepoxide 25-100 mg PO q4-6h or diazepam 5-10 mg PO/IV/IM q6-8h) provide superior seizure and delirium prevention 1, 2

• For patients WITH liver failure, advanced age, head trauma, respiratory failure, or obesity: Lorazepam 1-4 mg PO/IV/IM q4-8h (starting dose 6-12 mg/day total, then taper) 1

The 2022 French guidelines note that short-acting benzodiazepines in cirrhosis aim to avoid drug accumulation and encephalopathy, though this hasn't been validated in controlled trials - all benzodiazepines are affected by hepatic insufficiency 5. Importantly, over 70% of cirrhotic patients may not require benzodiazepines at all - use only when symptomatic 5.

Dosing Strategy:

• Use symptom-triggered approach with CIWA-Ar scoring 2
• CIWA-Ar >8 = moderate AWS (requires treatment) 2
• CIWA-Ar ≥15 = severe AWS (requires aggressive treatment) 2
• Limit benzodiazepine use to 10-14 days maximum due to abuse potential 2

Adjunctive Medications

When to Use:

• Carbamazepine 200 mg PO q6-8h: Alternative for seizure prevention if benzodiazepines contraindicated 1
• Haloperidol 0.5-5 mg PO q8-12h or 2-5 mg IM: ONLY as adjunct for agitation or hallucinations not controlled by benzodiazepines 1
• Avoid routine use of clomethiazole in critically ill patients 6
• Avoid therapeutic ethanol administration 6

Hepatic Complications Management

Supportive Care Orders:

• IV fluids for dehydration 1
• Comfortable, quiet environment 1
• Frequent vital sign monitoring 1
• Evaluate for: GI bleeding, pancreatitis, infection, head trauma, renal failure 1

Distinguishing Hepatic Encephalopathy from Alcohol Withdrawal Delirium:

• Time to onset: HE can occur anytime; AWS typically 6-24 hours after last drink 2, 7
• Activity level: AWS presents with hyperactivity; HE typically with hypoactivity 7
• Both can coexist - treat both if uncertain 7

Psychiatric and Addiction Medicine Consultation

Mandatory consultation for: 1

• Evaluation and acute management of AWS
• Long-term abstinence planning
• Assessment for medications for alcohol use disorder (MAUD)

Medications for Alcohol Use Disorder (MAUD)

Critical Gap: Only 2% of organizations include MAUD in order sets, yet this is essential for long-term outcomes 3. Consider initiating during hospitalization:

For patients WITHOUT severe liver disease:

• Naltrexone or acamprosate for maintaining abstinence 8, 9
• Nalmefene for reducing consumption 10

For patients WITH cirrhosis or severe liver disease:

• Baclofen is the only medication tested and shown safe/effective in cirrhotic patients (up to 80 mg/day) 2, 1, 5
• Acamprosate - no dose adjustment needed for liver disease 5
• Avoid: Naltrexone, nalmefene, disulfiram (contraindicated in hepatic insufficiency per labeling, though absolute contraindication debated) 5

Indications for ICU-Level Care

Escalate care for: 1

• Delirium tremens
• Withdrawal seizures
• Severe AWS unresponsive to standard benzodiazepine dosing
• Serious medical comorbidities (respiratory failure, cardiac issues)
• History of complicated withdrawal

Common Pitfalls to Avoid

1. Giving glucose before thiamine - can precipitate Wernicke encephalopathy 1
2. Using CIWA-Ar for diagnosis - it's a monitoring tool only; can be falsely elevated 1
3. Fixed-dose benzodiazepine schedules - symptom-triggered is superior 2
4. Long-acting benzodiazepines in cirrhosis - use lorazepam instead 1, 2
5. Forgetting MAUD initiation - hospitalization is ideal opportunity 3, 7
6. Benzodiazepines beyond 10-14 days - increases abuse risk 2
7. Inadequate magnesium repletion - check and replace aggressively 1